文献速递免疫规划

健康成人接种AZD1222/COVISHIELD基础免疫方案后对SARS-CoV-2变异株的体液与细胞免疫应答影响

Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults.
PubMed 文献 · Vaccine · 2025-02-11

研究纳入75名健康志愿者(含26名既往SARS-CoV-2感染者),评估AZD1222/COVISHIELD基础免疫后对SARS-CoV-2变异株的体液与细胞免疫应答。两剂接种后CMIA抗体均值从49 BAU/mL升至743 BAU/mL,PRNT几何平均滴度从3(95%CI 2-4)升至19(95%CI 11-34)。疫苗诱导对Delta变异株的交叉反应,既往感染者接种后抗体滴度更高,CD4+ T细胞应答普遍高于CD8+ T细胞。

要点

  • 两剂AZD1222接种后所有志愿者CMIA可检出抗体,仅64% PRNT阳性。
  • PRNT对Delta变异株滴度低于Wuhan-like株,血清转化率57%。
  • 既往感染者每剂接种后抗体滴度均更高,CD4+ T细胞应答高于CD8+ T细胞。

核心结论

  • AZD1222疫苗基础免疫可诱导稳健免疫应答,并对Delta变异株(VOC)产生交叉反应。
  • 随访期间 elevated 抗体滴度持续存在,且被第一剂加强针进一步提升。

研究设计与样本

  • 研究纳入75名健康成人志愿者,其中26名既往感染SARS-CoV-2。
  • 采用化学发光法(CMIA)、中和抗体试验(PRNT)和流式细胞术检测活化诱导标记(AIM)分别评估体液与细胞免疫应答。

主要发现

  • 两剂接种后CMIA抗体均值从49 BAU/mL升至743 BAU/mL,PRNT几何平均滴度从3(95%CI 2-4)升至19(95%CI 11-34)。
  • 接种后所有志愿者CMIA可检出抗体,仅64% PRNT阳性;第一剂和第二剂后CMIA血清转化率分别为91%和48%,PRNT血清转化率为59%。
  • PRNT对Delta变异株滴度低于Wuhan-like株,血清转化率为57%。
  • 尽管CMIA将所有志愿者归类为高应答者,部分志愿者PRNT和AIM显示无应答。
  • 既往感染者每剂接种后抗体滴度更高;所有变异株CD4+ T细胞应答普遍高于CD8+ T细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SARS-CoV-2 emerged rapidly as a pandemic, leading to the urgent development and authorization for the use of several vaccines, with questions relating to immunogenicity in previously infected people or to virus variants. As such, we sought to determine the humoral and cellular immune response of healthy adults to distinct SARS-CoV-2 variants upon AZD1222/COVISHIELD vaccination, using chemiluminescence (CMIA), neutralizing antibody (PRNT) and analysis of activation-induced marker (AIM) by flow cytometry, respectively. We enrolled 75 volunteers, including 26 individuals previously infected with SARS-CoV-2. Our findings demonstrated that AZD1222 vaccine induced increased levels of SARS-CoV-2-specific antibodies after two-dose vaccination scheme, as detected by CMIA (mean = 49 BAU/mL to 743 BAU/mL) and PRNT (GMT = 3, 95 % CI 2-4, to 19, 11-34). After vaccination, all volunteers presented detectable antibodies by CMIA while only 64 % presented positive PRNT. Seroconversion rates were 91 % and 48 % by CMIA and 59 % by PRNT after the first and second dose, respectively. The PRNT to Delta variant demonstrated lower titers as compared to Wuhan-like and a seroconversion of 57 %. Although by CMIA all volunteers were classified as high responders, some volunteers showed no response by PRNT and AIM. In general, previously infected volunteers had higher post-vaccination antibody titers after each dose. CD4+ T cell response was generally higher than CD8+ T cells for all variants. Overall, we observed that AZD1222 vaccination induced cross-reactivity to SARS-CoV-2 variants, in both cellular and humoral responses. During volunteer follow-up, we observed that the elevated antibody titers are lasting and were incremented by the first booster. In conclusion, our findings showed that AZD1222 vaccine was able to induce a robust immune response upon primary immunization, with cross-reactivity for the Delta VOC.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Capão A, Araújo MF, Tort LFL, et al. Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults. Vaccine. 2025. PMID: 39938313. doi:10.1016/j.vaccine.2025.126785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。